Routine panels mainly evaluate the deletion of 17p13 (TP53 deletion) and the t(4;14)(p16;q32) FGFR3-IGH translocation but do not cover the heterogeneity of MM. The gene discussed is TP53; the disease is Miyoshi myopathy.